EGFR and central nervous system cancer: To further confirm the impacts of EGFR genomic alterations on the TMZ efficiency, we constructed an independent validation cohort (Validation cohort) including 56 TMZ-treated glioma patients and collected formalin-fixed paraffin-embedded (FFPE) tissues for the WES, transcriptome, proteome, and phosphoproteome analysis (Fig. 5F).